These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 14211586)

  • 1. EVALUATION OF DEFEROXAMINE IN IRON OVERLOAD.
    HWANG YF; BROWN EB
    Arch Intern Med; 1964 Dec; 114():741-53. PubMed ID: 14211586
    [No Abstract]   [Full Text] [Related]  

  • 2. CHELATING AGENTS IN THE DIAGNOSIS AND TREATMENT OF IRON OVERLOAD IN THALASSEMIA.
    SMITH RS
    Ann N Y Acad Sci; 1964 Oct; 119():776-88. PubMed ID: 14219457
    [No Abstract]   [Full Text] [Related]  

  • 3. [DESFERRIOXAMINE (DF) AND DIETHYLENE TRIAMINE PENTA-ACETIC ACID TRISODIUM CALCIUM SALT (CA DTPA NA3) IN SIDEROSIS. 2].
    ALBAHARY C
    Presse Med (1893); 1965 Jan; 73():73-6. PubMed ID: 14234334
    [No Abstract]   [Full Text] [Related]  

  • 4. THE VALUE OF DESFERRIOXAMINE AS A DIAGNOSTIC TEST IN IRON OVERLOAD.
    PAWELSKI S; TOPOLSKA P; ROSZKOWSKI S; RADECKA K
    Pol Med Sci Hist Bull; 1965 Apr; 8():69-71. PubMed ID: 14319221
    [No Abstract]   [Full Text] [Related]  

  • 5. IRON DEFICIENCY ANAEMIA.
    RICHMOND J
    Br J Clin Pract; 1964 Nov; 18():641-52. PubMed ID: 14230847
    [No Abstract]   [Full Text] [Related]  

  • 6. IRON DEFICIENCY AND IRON OVERLOAD.
    SMITH ; RS
    Arch Dis Child; 1965 Aug; 40(212):343-63. PubMed ID: 14329251
    [No Abstract]   [Full Text] [Related]  

  • 7. Deferasirox.
    Stumpf JL
    Am J Health Syst Pharm; 2007 Mar; 64(6):606-16. PubMed ID: 17353569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STUDIES ON DESFERRIOXAMINE IN RELATION TO THE ABSORPTION OF IRON.
    BANNERMAN RM; MALPAS JS
    Br J Haematol; 1965 Jan; 11():15-20. PubMed ID: 14252103
    [No Abstract]   [Full Text] [Related]  

  • 9. FERROCENES AS HAEMATINICS.
    MADINAVEITIA JL
    Br J Pharmacol Chemother; 1965 Apr; 24(2):352-9. PubMed ID: 14320849
    [No Abstract]   [Full Text] [Related]  

  • 10. STUDIES IN THE DEVELOPMENT OF A SCREENING TEST OF IRON STORAGE DISEASE.
    BIEDERMANN P; FITZGERALD JD; KEBERLE H
    Acta Haematol; 1965 May; 33():297-307. PubMed ID: 14314665
    [No Abstract]   [Full Text] [Related]  

  • 11. [RESEARCH ON DESFERRIOXAMINE B. 3. THE CLINICAL USE OF DESFERRIOXAMINE B].
    VENTURA S; COLI L
    Haematologica; 1964; 49():252-73. PubMed ID: 14217827
    [No Abstract]   [Full Text] [Related]  

  • 12. [CHELATION].
    RENOUX M; MIKOL C
    Presse Med (1893); 1964 Dec; 72():3117-9. PubMed ID: 14221352
    [No Abstract]   [Full Text] [Related]  

  • 13. CLINICAL STUDIES OF STORAGE IRON WITH DESFERRIOXAMINE.
    GEVIRTZ NR; TENDLER D; LURINSKY G; WASSERMAN LR
    N Engl J Med; 1965 Jul; 273():95-7. PubMed ID: 14301206
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of storage iron by chelates.
    Harker LA; Funk DD; Finch CA
    Am J Med; 1968 Jul; 45(1):105-15. PubMed ID: 5658862
    [No Abstract]   [Full Text] [Related]  

  • 15. [THE EFFECT OF DESFERRIOXAMINE-B (DESFERAL) ON THE PLASMA CLEARANCE OF FE 59 IN HEALTHY PERSONS AND PATIENTS WITH PRIMARY HEMOCHROMATOSIS].
    OECHSLIN RJ; SCHMID JR
    Helv Med Acta; 1964 Nov; 31():604-9. PubMed ID: 14335472
    [No Abstract]   [Full Text] [Related]  

  • 16. Pathogenesis and management of iron overload in thalassemia.
    Hershko C
    Haematologica; 1975 Jun; 60(2):241-8. PubMed ID: 808456
    [No Abstract]   [Full Text] [Related]  

  • 17. [CHANGES IN THE IRON CONTENT OF BLOOD AND URINE IN PATIENTS WITH LEAD POISONING TREATED WITH COMPLEXION THERAPY (PENTACIN--CANA3 DTPA)].
    DASHASH A
    Gig Tr Prof Zabol; 1964 Dec; 8():12-6. PubMed ID: 14306658
    [No Abstract]   [Full Text] [Related]  

  • 18. DETERMINATION OF DESFERRIOXAMINE-BOUND IRON IN URINE.
    KAHN LB
    S Afr Med J; 1964 Jul; 38():463-4. PubMed ID: 14179950
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron chelators for clinical use.
    Tilbrook GS; Hider RC
    Met Ions Biol Syst; 1998; 35():691-730. PubMed ID: 9444773
    [No Abstract]   [Full Text] [Related]  

  • 20. TLc-A, the leading nanochelating-based nanochelator, reduces iron overload in vitro and in vivo.
    Kalanaky S; Hafizi M; Safari S; Mousavizadeh K; Kabiri M; Farsinejad A; Fakharzadeh S; Nazaran MH
    Int J Hematol; 2016 Mar; 103(3):274-82. PubMed ID: 26830968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.